Literature DB >> 12176914

Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants.

An D Billiau1, Sabine Fevery, Omer Rutgeerts, Willy Landuyt, Mark Waer.   

Abstract

A murine model of minor histocompatibility antigen-mismatched bone marrow transplantation (BMT) was used to study the role of timing of donor lymphocyte infusion (DLI) in eliciting graft-versus-host (GVH) and graft-versus-leukemia (GVL) reactivity. We gave DLI at weeks 3 and 12 after BMT and related its ability to induce a GVL effect with (1) evolution of T cell chimeric status and (2) the extent to which DLI could elicit lymphohematopoietic GVH (LHGVH) reactivity. All mice remained free of GVH disease, but only week 3 DLI chimeras exhibited a significant GVL response when challenged with host-type leukemia cells. In these week 3 DLI chimeras, host-reactive T cells were found to proliferate in vivo (5- [and-6]-carboxyfluorescein diacetate, succinimidyl esther [CFSE]-labeled DLI inocula, TCR-Vbeta6(+) T-cell frequency) and T-cell chimerism rapidly converted from mixed into complete donor type, indicating the occurrence of LHGVH reactivity. In week 12 chimeras, DLI elicited none of the activities noted at week 3. Yet, in both instances, splenocytes, recovered following DLI, generated an equally strong antihost proliferative response in a mixed lymphocyte reaction, thereby arguing against a decisive role of regulatory cells. The lack of in vivo LHGVH reactivity after week 12 DLI was associated with a substantially increased level of pre-existing host-type T-cell chimerism. We conclude that elicitation of a GVL effect may require LHGVH reactivity and that the reason why timing of DLI was critical for obtaining LHGVH reactivity and the desired GVL effect may lie in the evolution of chimeric status. A possible direct involvement of residual host-type antigen-presenting cells in eliciting LHGVH reactivity after DLI should be studied using models that allow chimerism analysis in non-T-cell lineages.

Entities:  

Mesh:

Year:  2002        PMID: 12176914     DOI: 10.1182/blood-2002-02-0419

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Recipient lymphocyte infusion in MHC-matched bone marrow chimeras induces a limited lymphohematopoietic host-versus-graft reactivity but a significant antileukemic effect mediated by CD8+ T cells and natural killer cells.

Authors:  Lien De Somer; Ben Sprangers; Sabine Fevery; Omer Rutgeerts; Caroline Lenaerts; Louis Boon; Mark Waer; An D Billiau
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

2.  Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.

Authors:  Ronjon Chakraverty; Hyeon-Seok Eom; Jessica Sachs; Jennifer Buchli; Pete Cotter; Richard Hsu; Guiling Zhao; Megan Sykes
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

3.  Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse.

Authors:  Nadira Durakovic; Vedran Radojcic; Mario Skarica; Karl B Bezak; Jonathan D Powell; Ephraim J Fuchs; Leo Luznik
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

4.  Visualization of immune response kinetics in full allogeneic chimeras.

Authors:  Gregory Elkin; Tatyana B Prigozhina; Shimon Slavin; Olga Gurevitch; Sofia Khitrin; Igor B Resnick
Journal:  Am J Blood Res       Date:  2011-08-22

5.  Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3.

Authors:  Hui-Hui Ma; Judy Ziegler; Cuiling Li; Antonia Sepulveda; Ahmed Bedeir; Jennifer Grandis; Suzanne Lentzsch; Markus Y Mapara
Journal:  Cell Immunol       Date:  2011-02-04       Impact factor: 4.868

Review 6.  Prevention of GVHD without losing GVL effect: windows of opportunity.

Authors:  Ping Zhang; Benny J Chen; Nelson J Chao
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

Review 7.  Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Jian-Ming Li; Cynthia R Giver; Ying Lu; Mohammad S Hossain; Mojtaba Akhtari; Edmund K Waller
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

8.  The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia.

Authors:  Ronjon Chakraverty; Megan Sykes
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

9.  Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice.

Authors:  Bruno Nervi; Michael P Rettig; Julie K Ritchey; Hanlin L Wang; Gerhard Bauer; Jon Walker; Mark L Bonyhadi; Ronald J Berenson; Julie L Prior; David Piwnica-Worms; Jan A Nolta; John F DiPersio
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

10.  Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation.

Authors:  Tomomi Toubai; Yaping Sun; Gary Luker; Jun Liu; Kathryn E Luker; Isao Tawara; Rebecca Evers; Chen Liu; Nathan Mathewson; Chelsea Malter; Evelyn Nieves; Sung Choi; Kenneth M Murphy; Pavan Reddy
Journal:  Blood       Date:  2013-03-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.